In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth

Oncogene

Volumn 34, Issue 21, 2015, Pages 2764-2776

  Jiang, N ^a,b   Hjorth Jensen, K ^a   Hekmat, O ^a   Iglesias Gato, D ^a   Kruse, T ^a   Wang, C ^b   Wei, W ^b   Ke, B ^b   Yan, B ^b   Niu, Y ^b   Olsen, J V ^a   Flores Morales, A ^a  

^a University of Copenhagen   (Denmark)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IPA 3; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; P21 ACTIVATED KINASE 2; PF 3758309; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOPEPTIDE; PROTEIN KINASE B; PROTEIN KINASE LYN; PROTEIN SERINE THREONINE KINASE INHIBITOR; S6 KINASE; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; VERTEPORFIN; ANDROGENS; PROTEOME; PYRAZOLES; PYRROLES; RECEPTORS, ANDROGEN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH RATE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PHOSPHOPROTEOMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TUMOR XENOGRAFT; ANIMALS; CELL LINE, TUMOR; DRUG EFFECTS; HUMANS; METABOLISM; METHODS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PHYSIOLOGY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION;

MUS;

ANDROGENS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEOME; PROTEOMICS; PYRAZOLES; PYRROLES; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84930272574     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.206     Document Type: Article

References (55)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
2. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 2009; 73(Suppl): S4-S10.
3. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
4. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-243.
5. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-406.
6. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999; 91: 1574-1580.
7. Saramaki O, Visakorpi T. Chromosomal aberrations in prostate cancer. Front Biosci 2007; 12: 3287-3301.
8. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011; 19: 792-804.
9. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-586.
10. Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B et al. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTORdependent growth. Am J Pathol 2009; 174: 1869-1879.
11. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-1818.
12. Schayowitz A, Sabnis G, Goloubeva O, Njar VC, Brodie AM. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. Br J Cancer 2010; 103: 1001-1007.
13. Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int 2012; 110: 1729-1735.
14. Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M et al. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res 2009; 69: 7466-7472.
15. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006; 127: 635-648.
16. Pan C, Olsen JV, Daub H, Mann M. Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteom 2009; 8: 2796-2808.
17. Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ et al. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 2010: 3ra3.
18. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54: 2577-2581.
19. Visakorpi T, Kylmala T, Tainio H, Koivula T, Tammela T, Isola J. High cell proliferation activity determined by DNA flow cytometry predicts poor prognosis after relapse in prostate cancer. Eur J Cancer 1994; 30A: 129-130.
20. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105: 12182-12187.
21. Geiger T, Cox J, Ostasiewicz P, Wisniewski JR, Mann M. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods 2010; 7: 383-385.
22. Lopez-Casillas F, Bai DH, Luo XC, Kong IS, Hermodson MA, Kim KH. Structure of the coding sequence and primary amino acid sequence of acetyl-coenzyme A carboxylase. Proc Natl Acad Sci USA 1988; 85: 5784-5788.
23. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310.
24. Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
25. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007; 25: 903-915.
26. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13: 246-257.
27. Ye DZ, Field J. PAK signaling in cancer. Cell Logist 2012; 2: 105-116.
28. Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream. Cell 2007; 129: 1261-1274.
29. Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 2007; 67: 7106-7112.
30. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
31. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.
32. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: A networkbased method for gene-set enrichment visualization and interpretation. PLoS One 2010; 5: E13984.
33. Mukherjee R, McGuinness DH, McCall P, Underwood MA, Seywright M, Orange C et al. Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. Br J Cancer 2011; 104: 1920-1928.
34. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci USA 2013; 110: E4762-E4769.
35. Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 2008; 27: 7180-7191.
36. Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A et al. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 2008; 22: 2172-2177.
37. Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY et al. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res 2009; 69: 7803-7810.
38. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001; 47: 212-221.
39. Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J et al. Smallmolecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci USA 2010; 107: 9446-9451.
40. Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008; 15: 322-331.
41. Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012; 26: 1300-1305.
42. Laplante M, Sabatini DM.. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
43. D'Antonio JM, Ma C, Monzon FA, Pflug BR. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. Prostate 2008; 68: 698-714.
44. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 2012; 26: 54-68.
45. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41-51.
46. Das Thakur M, Feng Y, Jagannathan R, Seppa MJ, Skeath JB, Longmore GD. Ajuba LIM proteins are negative regulators of the Hippo signaling pathway. Curr Biol 2010; 20: 657-662.
47. Mann M, Kulak NA, Nagaraj N, Cox J. The coming age of complete, accurate, and ubiquitous proteomes. Mol Cell 2013; 49: 583-590.
48. Lundby A, Secher A, Lage K, Nordsborg NB, Dmytriyev A, Lundby C et al. Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 2012; 3: 876.
49. Cox J, Mann M.. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008; 26: 1367-1372.
50. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. Andromeda: A peptide search engine integrated into the MaxQuant environment. J Proteome Res 2011; 10: 1794-1805.
51. Olsen JV, Mann M et al. Status of large-scale analysis of post-translational modifications by mass spectrometry. Mol Cell Proteomics 2013; 12: 3444-3452.
52. Hekmat O, Munk S, Fogh L, Yadav R, Francavilla C, Horn H et al. TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells. J Proteome Res 2013; 12: 4136-4151.
53. Olsen JV, Schwartz JC, Griep-Raming J, Nielsen ML, Damoc E, Denisov E et al. A dual pressure linear ion trap Orbitrap instrument with very high sequencing speed. Mol Cell Proteom 2009; 8: 2759-2769.
54. Zhang G, Kelstrup CD, Hu XW, Kaas Hansen MJ, Singleton MR, Olsen JV et al. The Ndc80 internal loop is required for recruitment of the Ska complex to establish end-on microtubule attachment to kinetochores. J Cell Sci 2012; 125(Part 13): 3243-3253.
55. Chuan YC, Iglesias-Gato D, Fernandez-Perez L, Cedazo-Minguez A, Pang ST, Norstedt G et al. Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene 2009; 29: 1531-1542.